Valeant Pharmaceuticals (NYSE:VRX) has attracted a great deal of positive Street buzz after last Tuesday’s posted third quarter beat. BMO analyst Gary Nachman is out with a cautiously optimistic bumping up his price target a dollar. Yet, it is not all clear, cloudless skies for the biotech giant quite yet. Why is Nachman cautious?
Story Continues
